FP
Flagship Pioneering Portfolio holdings
AUM
$268M
This Quarter Return
+21.61%
1 Year Return
-54.4%
3 Year Return
-51.2%
5 Year Return
+66.7%
10 Year Return
–
AUM
$2.64B
AUM Growth
+$2.64B
(+29%)
Cap. Flow
+$231M
Cap. Flow
% of AUM
8.72%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
–
Top Buys
| 1 |
KLDO
Kaleido Biosciences, Inc. Common Stock
KLDO
|
$252M |
Top Sells
| 1 |
Denali Therapeutics
DNLI
|
$21.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Moderna
MRNA
$9.22B
| $1.2B | 45.29% |
58,807,379
| – | – |
|
|
RUBY
2
DELISTED
Rubius Therapeutics, Inc
RUBY
| $693M | 26.23% |
38,296,526
| – | – |
|
|
KLDO
3
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $252M | 9.53% |
+17,360,710
| New | +$252M |
|
|
4
Denali Therapeutics
DNLI
$2.22B
| $186M | 7.04% |
8,005,747
-913,002
| -10% | -$21.2M |
|
|
EVLO
5
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
| $146M | 5.52% |
18,233,403
| – | – |
|
6
Seres Therapeutics
MCRB
$170M
| $87.1M | 3.3% |
12,682,876
| – | – |
|
7
Quanterix
QTRX
$207M
| $52.4M | 1.99% |
2,030,495
| – | – |
|
|
SYRS
8
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $29.3M | 1.11% |
3,204,437
| – | – |
|